ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Erik Fosse
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garred, P.
Right arrow Articles by Mollnes, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garred, P.
Right arrow Articles by Mollnes, T. E.

Ann Thorac Surg 1993;55:694-699
© 1993 The Society of Thoracic Surgeons

Articles

Calprotectin and complement activation during major operations with or without cardiopulmonary bypass

Peter Garred, MD, PhD*,a,b, Erik Fosse, MD, PhDa,b, Magne K. Fagerhol, MD, PhDa,b, Vibeke Videm, MD, PhDa,b, Tom Eirik Mollnes, MD, PhDa,b

a Institute of Immunology and Rheumatology, the National Hospital Norway
b Section of Thoracic and Cardiovascular Surgery, Department of Surgery, and Bloodbank and Department of Immunology, Institute for Experimental Medical Research, Ullevaal University Hospital, Oslo, Norway

Accepted for publication June 26, 1992.

* Address reprint requests to Dr Garred, Tissue Typing Laboratory, Rigshospitalet, Tagensvej 20, DK-2200 Copenhagen N, Denmark.

Plasma concentrations of the granulocyte cell marker calprotectin were assessed during operation and 24 hours postoperatively in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass, abdominal aneurysmectomy with implantation of an aortic graft, or thoracotomy without implantation of synthetic material. The concentration of calprotectin increased significantly (p < 0.01) in all three groups. Ten of the 30 patients in the group undergoing cardiopulmonary bypass received methylprednisolone at the start of the operation. No difference in calprotectin concentration was seen between the two subgroups (p > 0.05). Plasma concentration of calprotectin was shown to increase rapidly in patients undergoing cardiopulmonary bypass and aneurysmectomy, in whom complement activation also took place. However, the caprotectin concentration increased slowly during the operation and the postoperative period in patients undergoing a thoracotomy, in whom complement was not activated. At wound closure the calprotectin concentration was significantly elevated in the cardiopulmonary bypass and aneurysmectomy groups compared with the thoracotomy group (p < 0.05). The calprotectin concentration remained elevated during the postoperative period in all three groups. Our results indicate that calprotectin may serve as a suitable cellular marker when the biocompatibility of artificial surfaces is studied.




This article has been cited by other articles:


Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
H. A. Hennein
Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. Fosse, O. Moen, E. Johnson, G. Semb, V. Brockmeier, T. E. Mollnes, M. K. Fagerhol, and P. Venge
Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass
Ann. Thorac. Surg., August 1, 1994; 58(2): 472 - 477.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.